Carlyn Tan, MD, Discusses Teclistamab Treatment for Multiple Myeloma

Dr. Tan, of the Memorial Sloan Kettering Cancer Center, discussed her retrospective study on multiple myeloma (MM) presented at the 65th American Society of Hematology Annual Meeting & Exposition.

The study compared characteristics, step-up dosing, and incidence and management of cytokine release syndrome in patients who received teclistamab for relapsed or refractory MM.

Dr. Tan and colleagues used the Premier Healthcare Database to acquire patient information for treatment patterns.

“We found that the first group of these early-initiator patients was mostly elderly, pretty diverse, and had significant comorbidities,” Dr. Tan said. “However, they were able to complete their step-up dosing and receive teclistamab either during a three-day or two-day dosing interval.”